<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Sepracor Incorporated</title>
	<atom:link href="http://www.stockbloghub.com/tag/sepracor-incorporated/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SEPR) Dainippon Sumitomo Pharma Acquires Sepracor</title>
		<link>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333</link>
		<comments>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333#comments</comments>
		<pubDate>Thu, 03 Sep 2009 20:46:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Incorporated]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14333</guid>
		<description><![CDATA[Today morning, Japanese pharmaceutical company Dainippon Sumitomo Pharma Co., Ltd. confirmed that it signed a definitive agreement to buy U.S. pharmaceutical company Sepracor Inc. (SEPR). The deal has been valued at $23 per share or $2.6 billion. The market was abuzz with rumors yesterday regarding the potential takeover. The rumors led to a 26.46% increase in Sepracor’s stock price. Trading was halted in the afternoon with Sepracor shares closing at $22.80. This acquisition is the latest in a series of deals conducted by Japanese companies that are looking to tap the U.S. pharmaceutical market – the biggest in the world. Last year, we saw four such deals take place including Eisai’s acquisition of MGI Pharma, Takeda’s acquisition of Millennium Pharma and Shionogi’s acquisition of Sciele. Finally, Daiichi-Sankyo acquired a stake ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MEDX) Top Delaware Funds &#8211; Mutual Fund Education</title>
		<link>http://www.stockbloghub.com/2009/09/02/medx-top-delaware-funds-mutual-fund-education/14160</link>
		<comments>http://www.stockbloghub.com/2009/09/02/medx-top-delaware-funds-mutual-fund-education/14160#comments</comments>
		<pubDate>Wed, 02 Sep 2009 20:22:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14160</guid>
		<description><![CDATA[Delaware Trend A (DELTX) seeks long-term capital appreciation by primarily investing in small, growth-oriented or emerging companies. The fund uses a bottom-up approach to create a portfolio and normally maintains its position in a stock until it fully achieves its growth potential. It analyzes price-to-earnings ratios, estimated growth rates, market capitalization and cash flows to determine the attractiveness of a company. Medarex Inc. (MEDX), Sepracor Inc. (SEPR) and Abraxis BioScience Inc. (ABII) are among the fund’s key holdings. Delaware International Value Equity A (DEGIX) was incepted in October 1991. The investment seeks long-term growth without undue risk to principal. The fund invests primarily in equity securities of issuers from foreign countries but may invest more than 25% of assets in the securities of issuers located in the same country. As ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/medx-top-delaware-funds-mutual-fund-education/14160/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Sepracor Incorporated Doubled the Consensus Earnings Forecast</title>
		<link>http://www.stockbloghub.com/2009/08/27/sepracor-incorporated-doubled-the-consensus-earnings-forecast/13579</link>
		<comments>http://www.stockbloghub.com/2009/08/27/sepracor-incorporated-doubled-the-consensus-earnings-forecast/13579#comments</comments>
		<pubDate>Thu, 27 Aug 2009 20:52:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13579</guid>
		<description><![CDATA[Sepracor Inc (SEPR) shares are on a bullish run with a recent earnings report adding fuel to the fire. Company Description Sepracor develops safer, purer, and more effective drugs to improve on already existing pharmaceuticals. The company develops compounds to improve a therapy&#8217;s efficacy, side-effects, or both. Crushed Estimates On Jul 24 Sepracor reported second-quarter results that included an 11% pop in revenue, up to $326 million. Earnings per share came in at 72 cents, almost double the Zacks Consensus Estimate of 38 cents. This was the third consecutive surprise. Raising Guidance Management went on to raise full-year guidance Incorporatedreasing estimated revenue to $1.25 billion, give or take $25 million. Earnings per share are expected to be between $2.55 and $2.90, up from between $2.10 and $2.70. Estimtes Follow After ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/sepracor-incorporated-doubled-the-consensus-earnings-forecast/13579/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

